Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cobomarsen · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Part A, MF | EXPERIMENTAL | Intratumoral Injection of cobomarsen |
| Part B, MF | EXPERIMENTAL | Subcutaneous, intravenous or a combination of systemic and intratumoral administration of cobomarsen with or without stable background therapy |
| Part C, MF | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Part D, CLL | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Part E, DLBCL, activated B-cell (ABC) subtype | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Part F, ATLL | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Name | Type | Description |
|---|---|---|
| Cobomarsen | DRUG | - |
Inclusion Criteria: * Parts A-C only: Patients must have biopsy proven MF, clinical stage I, II, or III (excluding visceral or nodal involvement), and must be refractory to or intolerant of established therapies for their condition * Part D only: Patients diagnosed with CLL who are intolerant to, o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | - | Undisclosed |
Cobomarsen is an investigational small molecule being developed for Cutaneous T-cell Lymphoma (CTCL), a type of non-Hodgkin lymphoma that affects the skin. It is also being studied in related blood cancers including Mycosis Fungoides, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, and Adult T-Cell Leukemia/Lymphoma.
Cobomarsen is being developed by CASI Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol CASI. The company is conducting clinical research on this investigational oncology drug candidate.
Cobomarsen is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 clinical trial has been completed, and the drug remains in early-stage clinical development for Cutaneous T-cell Lymphoma and related conditions.
Cobomarsen has one completed clinical trial registered as NCT02580552, titled "Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL." This Phase 1 study enrolled 66 participants in the United States and included patients with Cutaneous T-cell Lymphoma and other blood cancers.
Yes, Cobomarsen is also known as MRG-106. The clinical trial NCT02580552 used the name MRG-106 in its title, and this alternative name refers to the same investigational drug candidate being developed by CASI Pharmaceuticals.